10 completed, 3 terminated, 1 unknown, 1 withdrawn. 10 Phase 2, 5 Phase 1, 3 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Terminated 3, Unknown 1 |
| Phase 1 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Terminated 2, Withdrawn 1 |
| Phase 4 | 1 | Completed 1 |
Follow Mateon Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects Artemisinin, Dexamethasone - Covid19 | Phase 4 | Completed | Mateon Therapeutics | 120 | 2020-09-30 | 2021-09-09 |
| FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer Fosbretabulin tromethamine, Placebo - Platinum Resistant Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Mateon Therapeutics | 70 | 2016-06-01 | 2025-03-24 |
| Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine - Acute Myelogenous Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | Mateon Therapeutics | 105 | 2015-10-01 | 2018-06-04 |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Fosbretabulin + paclitaxel + carboplatin, Placebo + paclitaxel + carboplatin - Anaplastic Thyroid Cancer | Phase 3 | Withdrawn | Mateon Therapeutics | 2015-03-01 | 2014-05-01 | |
| Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study fosbretabulin - Neuroendocrine Tumors | Phase 2 | Completed | Mateon Therapeutics | 7 | 2014-12-01 | 2018-04-17 |
| A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers fosbretabulin tromethamine - Neuroendocrine Tumors | Phase 2 | Completed | Mateon Therapeutics | 18 | 2014-09-01 | 2017-12-05 |
| PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer Pazopanib, Fosbretabulin - Ovarian Neoplasms, Neoplasms, Ovarian | Phase 1 / Phase 2 | Terminated | The Christie NHS Foundation Trust | 21 | 2014-09-01 | 2021-05-17 |
| Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden Combretastatin A1 Diphosphate (OXi4503) - Neoplasm Metastasis | Phase 1 | Completed | Mateon Therapeutics | 16 | 2009-07-01 | 2011-08-23 |
| Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) fosbretabulin, Saline - Polypoidal Choroidal Vasculopathy | Phase 2 | Completed | Mateon Therapeutics | 20 | 2009-07-01 | 2011-11-01 |
| A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer Fosbretabulin, Carboplatin, Paclitaxel - Tumors | Phase 2 | Completed | Mateon Therapeutics | 63 | 2008-03-01 | 2015-02-09 |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer CA4P, paclitaxel, carboplatin - Anaplastic Thyroid Cancer | Phase 2 / Phase 3 | Terminated | Mateon Therapeutics | 80 | 2007-08-01 | 2014-06-09 |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors Combretastatin A4 Phosphate (CA4P), Bevacizumab (Avastin) - Tumors | Phase 1 | Completed | Mateon Therapeutics | 20 | 2006-09-01 | 2011-10-31 |
| Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors OXi4503 - Solid Tumors | Phase 1 | Completed | Mateon Therapeutics | 40 | 2005-07-01 | 2011-10-31 |
| Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Combretastatin A-4 Phosphate - Choroidal Neovascularization, Myopia, Degenerative | Phase 2 | Completed | Mateon Therapeutics | 23 | 2005-03-01 | 2011-11-01 |
| Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin - Cancer, Tumor | Phase 2 | Completed | Mateon Therapeutics | 13 | 2005-03-01 | 2011-11-01 |
Neoplasms (3) · Neoplasm Metastasis (2) · Neuroendocrine Tumors (2) · Thyroid Carcinoma, Anaplastic (2) · Thyroid Neoplasms (2) · COVID-19 (1) · Carcinoid Tumor (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Choroidal Neovascularization (1) · Head and Neck Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Liver Neoplasms (1) · Lung Neoplasms (1)
fosbretabulin (10) · Carboplatin (4) · Paclitaxel (4) · combretastatin (3) · Bevacizumab (2) · Oxi 4503 (2) · Sodium Chloride (2) · Cytarabine (1) · Dexamethasone (1) · artemisinin (1) · pazopanib (1)
United States (8) · United Kingdom (4) · India (2) · Australia (1) · Belarus (1) · Belgium (1) · Bulgaria (1) · Egypt (1) · Germany (1) · Hong Kong (1) · Israel (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1)
Gordon Jayson (1) · Gordon Rustin (1) · Harish Dave, MD (1) · Hillori Connors, MS (1) · Jai Balkissoon, MD, FACS (1) · Jason Lickliter, MD (1) · Julie A Sosa, MD (1) · Julie A. Sosa, MD, FACS (1) · Lisa Licitra, MD (1) · Marcia Brose, MD, PhD (1) · Michael Brown, MD (1) · Michael Millward, MD (1) · Mukesh Kumar (1) · Paul Mainwaring, MD (1) · Paul Nathan, MD (1)